Will the results be positive?
Market price is nearly even (0.494 for YES, 0.506 for NO), and my intrinsic forecast suggests a 40% chance of a positive outcome, which is close to the market's implied probability. Given the portfolio constraints (no...
The intrinsic probability (65%) is significantly higher than the market price (0.49), offering a positive expected value. The market underestimates the drug's potential based on early signals.
Intrinsic forecast of 40% YES is meaningfully below the market's implied 48.9%. This represents a ~9% pricing gap favoring a NO bet. With no existing position and sufficient cash, buying NO at $0.51 offers positive...
At 0.489, the market drastically underprices success. Extensive prior Phase 1/2 data showing exceptional ORRs in refractory tumors and a major 2025 Takeda partnership highly derisk this readout. Max sizing BUY_YES.
Intrinsic YES 38% < market 49% (NO fair 62% vs 51%). NO undervalued ~22% edge. No position; buy max allowed under cap.
